Inici › Càncer de pulmó de cèl·lules no petites › Illinois › Bloomington
Assaigs clínics de Càncer de pulmó de cèl·lules no petites a Bloomington, IL
11 estudis de Càncer de pulmó de cèl·lules no petites busquen participants en centres de Bloomington i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ReclutantFase 3
- Illinois CancerCare-Bloomington, Bloomington
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
ReclutantFase 2
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ReclutantFase 3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · a 2 mi
- Carle Cancer Institute Normal, Normal · a 2 mi
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
ReclutantFase 3
- Illinois CancerCare- Bloomington, Bloomington
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ReclutantFase 3
- Illinois CancerCare - Bloomington, Bloomington
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
ReclutantFase 2
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutantFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2
- Illinois CancerCare-Bloomington, Bloomington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ReclutantFase 2/3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · a 2 mi
- Carle Cancer Institute Normal, Normal · a 2 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
ReclutantEstudi observacional
- Illinois CancerCare-Bloomington, Bloomington
- Carle Cancer Institute Normal, Normal · a 2 mi
Assaigs de Càncer de pulmó de cèl·lules no petites en altres ciutats
- Houston, TX145 estudis
- New York City, NY120 estudis
- Arlington, VA104 estudis
- Nashville, TN97 estudis
- Boston, MA90 estudis
- Los Angeles, CA87 estudis
- St. Louis, MO73 estudis
- Chicago, IL61 estudis
- Baltimore, MD60 estudis
- San Antonio, TX59 estudis
- Columbus, OH56 estudis
- Washington, DC55 estudis
Altres estudis a Bloomington
- Càncer de pulmó9 estudis
- Càncer de pròstata7 estudis
- Càncer colorrectal7 estudis
- Carcinoma de cèl·lules escamoses de cap i coll6 estudis
- Càncer de pàncrees5 estudis
- Melanoma5 estudis
- Càncer hipofaringi5 estudis
- Càncer de laringe5 estudis
- Càncer oral5 estudis
- Càncer de mama5 estudis
- Càncer de ronyó (carcinoma de cèl·lules renals)4 estudis
- Leucèmia mieloide aguda4 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.